Decibel Therapeutics, Inc.
NASDAQ: DBTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurence E. Reid
- Employees
- 68
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $123.4M
- Website
- https://www.decibeltx.com
Loading DBTX…
Loading profile data…Frequently asked questions about DBTX
What does Decibel Therapeutics, Inc. (DBTX) do?
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-...
Where does DBTX trade?
Decibel Therapeutics, Inc. (DBTX) trades on the NASDAQ Global Select.
What sector is DBTX in?
Decibel Therapeutics, Inc. (DBTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Decibel Therapeutics, Inc.?
Laurence E. Reid is the chief executive officer of Decibel Therapeutics, Inc. (DBTX).
Where is Decibel Therapeutics, Inc. headquartered?
Decibel Therapeutics, Inc. is headquartered in United States.
Does DBTX pay a dividend?
Decibel Therapeutics, Inc. (DBTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DBTX go public?
Decibel Therapeutics, Inc. (DBTX) completed its initial public offering in 2021.